By analogicus. CC0 Creative Commons.

It was a complex week for the Mexican healthcare sector. Worried about the federal government’s debts, Jorge Alcocer, President-Elect Andrés Manuel López Obrador’s pick for Minister of Health, announced a review of hospitals built under the Public Private Partnership (PPP) model. The Economic Commission for Latin America and the Caribbean denounced unequal access to healthcare services for Mexicans, the National Human Rights Commission called air pollution a violation of human rights, the media states that healthcare services faced a 20 percent budget cut and the country gained notoriety for its stigma against mental diseases.

In international news, new treatment for hemophilia A gets FDA approval, Novartis announces construction of another plant and GSK spinoff to test non-hormonal therapy for menopause.

Mexico Health Review spoke with Genesys’ Sergio Mejia on the role Big Data and the Internet of Things will have in healthcare practices.

Have a dose of last week’s highlights:

 

National

National Human Rights Commission denounces air pollution as a human rights violation as it acts as a barrier to healthy environment and an adequate lifestyle.

Mexico is the second country in the world with worst stigma against mental disease.

The Economic Commission for Latin America and the Caribbean called for equal access to healthcare to increase Mexico’s productivity.

Budget cuts of 20 percent in the healthcare sector hit Mexicans during the current presidential administration.

Mexico’s President-Elect promised to cancel major medical expenses insurance policies for public workers. MetLife is not worried.

 

International

FDA approves Bayer’s long-acting treatment for hemophilia A, Jivi, which is expected to directly compete with Roche’s Hemlibra.

Novartis to build new facility in Switzerland which will focus on cell and gene therapies.

KaNDy Therapeutics, Glaxo Smith Kline spin-off, raises US$32 million to test non-hormonal treatment to menopause symptoms.

Tagged with →  
Share →

Leave a Reply

Your email address will not be published. Required fields are marked *